Norgine focuses on patient access to treatments

Norgine is focused on giving patients across the globe access to innovative products, it has claimed.

The European pharmaceutical company has announced PharmaSwiss will market a number of its treatments in Eastern Europe.

One such therapy is Moviprep, which is a novel patent designed to cleanse bowels before a colonoscopy.

Developed and currently marketed in Europe by Norgine, the product can also be used for other situations where a clean bowel is needed.

The business’ US partner Salix is responsible for the commercialisation and sales of the treatment across the Atlantic.

Chief executive officer Peter Stein commented: “This agreement further strengthens Norgine’s commitment to bring innovative products to the market for the benefit of patients worldwide.”

Earlier this month, the company announced Jose Garcia Carrasco had been appointed as its new general manager for Iberia.

He has over 20 years of pharmaceutical experience in the Spanish and Portuguese markets. Norgine asserted the new appointment would strengthen its management infrastructure in Iberia.